Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Wyatt B. Messenger, Robert M. Beardsley, Christina Flaxel

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fuocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fuocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fuocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fuocinolone acetonide intravitreal devices.

Original languageEnglish (US)
Pages (from-to)425-434
Number of pages10
JournalDrug Design, Development and Therapy
Volume7
DOIs
StatePublished - May 23 2013

Fingerprint

Fluocinolone Acetonide
Macular Edema
Equipment and Supplies
Intraocular Pressure
Visual Acuity
Light Coagulation
Therapeutics
Standard of Care
Cataract
Lasers
Drug Therapy

Keywords

  • Anti-VEGF
  • Dexamethasone
  • Diabetic macular edema
  • Fuocinolone
  • Triamcinolone

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. / Messenger, Wyatt B.; Beardsley, Robert M.; Flaxel, Christina.

In: Drug Design, Development and Therapy, Vol. 7, 23.05.2013, p. 425-434.

Research output: Contribution to journalArticle

@article{6d4e7b00fad64b8c8f014d833572ebce,
title = "Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema",
abstract = "Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fuocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fuocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fuocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fuocinolone acetonide intravitreal devices.",
keywords = "Anti-VEGF, Dexamethasone, Diabetic macular edema, Fuocinolone, Triamcinolone",
author = "Messenger, {Wyatt B.} and Beardsley, {Robert M.} and Christina Flaxel",
year = "2013",
month = "5",
day = "23",
doi = "10.2147/DDDT.S44427",
language = "English (US)",
volume = "7",
pages = "425--434",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

AU - Messenger, Wyatt B.

AU - Beardsley, Robert M.

AU - Flaxel, Christina

PY - 2013/5/23

Y1 - 2013/5/23

N2 - Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fuocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fuocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fuocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fuocinolone acetonide intravitreal devices.

AB - Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fuocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fuocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fuocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fuocinolone acetonide intravitreal devices.

KW - Anti-VEGF

KW - Dexamethasone

KW - Diabetic macular edema

KW - Fuocinolone

KW - Triamcinolone

UR - http://www.scopus.com/inward/record.url?scp=84878345972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878345972&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S44427

DO - 10.2147/DDDT.S44427

M3 - Article

C2 - 23737661

AN - SCOPUS:84878345972

VL - 7

SP - 425

EP - 434

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -